TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic tissue reconstruction, announced today the successful implantations of the first patients with its COAPTIUM Connect Sutureless Nerve Coaptation System as part of its peripheral nerve repair study in Australia. The procedures were performed as part of an ongoing clinical trial conducted by Dr Michael Wagels at the Princess Alexandra Hospital, supported by the Translational Research Institute’s Translational Trials team, and by Prof Randy Bindra at the Gold Coast University Hospital.
The COAPTIUM Connect System has been designed for sutureless and consistent nerve repair. It leverages TISSIUM’s unique biopolymer platform and is comprised of a biodegradable light-activated surgical adhesive and a protective coaptation “chamber.”
Organized by the Société Française de Cosmétologie and supported by major names in the international…
Shruti Ghosh 3 April 2025 American cosmetic trends are changing fast. Imagine you’re getting ready…
19 May 2025 The beauty industry is undergoing significant transformation, driven by sustainability, innovation, and…